Allergan PLC (AGN) Position Raised by Pillar Pacific Capital Management LLC
Pillar Pacific Capital Management LLC boosted its stake in shares of Allergan PLC (NYSE:AGN) by 0.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,136 shares of the company’s stock after buying an additional 72 shares during the period. Pillar Pacific Capital Management LLC’s holdings in Allergan PLC were worth $4,868,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of the stock. Balentine LLC increased its stake in Allergan PLC by 0.4% in the second quarter. Balentine LLC now owns 1,706 shares of the company’s stock valued at $394,000 after buying an additional 7 shares during the last quarter. Motco increased its stake in Allergan PLC by 0.7% in the second quarter. Motco now owns 1,202 shares of the company’s stock valued at $278,000 after buying an additional 8 shares during the last quarter. Pure Financial Advisors Inc. increased its stake in Allergan PLC by 0.4% in the second quarter. Pure Financial Advisors Inc. now owns 2,596 shares of the company’s stock valued at $600,000 after buying an additional 10 shares during the last quarter. Lenox Wealth Advisors Inc. increased its stake in Allergan PLC by 0.3% in the third quarter. Lenox Wealth Advisors Inc. now owns 4,348 shares of the company’s stock valued at $1,001,000 after buying an additional 14 shares during the last quarter. Finally, YHB Investment Advisors Inc. increased its stake in Allergan PLC by 0.4% in the second quarter. YHB Investment Advisors Inc. now owns 4,899 shares of the company’s stock valued at $1,132,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 86.89% of the company’s stock.
Allergan PLC (NYSE:AGN) traded up 1.39% during mid-day trading on Tuesday, reaching $192.64. The company’s stock had a trading volume of 5,481,969 shares. Allergan PLC has a 1-year low of $184.50 and a 1-year high of $322.68. The stock’s 50 day moving average price is $211.32 and its 200 day moving average price is $233.30. The stock has a market capitalization of $72.26 billion, a P/E ratio of 5.40 and a beta of 1.08.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. The business earned $3.62 billion during the quarter, compared to analyst estimates of $3.73 billion. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.48 earnings per share. Analysts expect that Allergan PLC will post $13.37 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be issued a $0.70 dividend. This is an increase from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 annualized dividend and a yield of 1.45%.
TRADEMARK VIOLATION WARNING: “Allergan PLC (AGN) Position Raised by Pillar Pacific Capital Management LLC” was posted by Daily Political and is the propert of of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The original version of this article can be read at http://www.dailypolitical.com/2016/11/29/allergan-plc-agn-position-raised-by-pillar-pacific-capital-management-llc.html.
A number of analysts have recently commented on the company. Deutsche Bank AG set a $278.00 target price on Allergan PLC and gave the stock a “buy” rating in a research note on Saturday, October 15th. Vetr downgraded Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 target price on the stock. in a research note on Monday, August 8th. RBC Capital Markets restated an “outperform” rating and issued a $300.00 target price (down previously from $307.00) on shares of Allergan PLC in a research note on Wednesday, August 10th. Leerink Swann set a $294.00 target price on Allergan PLC and gave the stock a “buy” rating in a research note on Monday, August 8th. Finally, JPMorgan Chase & Co. set a $325.00 target price on Allergan PLC and gave the stock a “buy” rating in a research note on Friday, August 5th. Seven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $289.11.
In other news, CEO Brent L. Saunders acquired 5,250 shares of the company’s stock in a transaction dated Monday, November 21st. The stock was acquired at an average cost of $189.13 per share, for a total transaction of $992,932.50. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Maria Teresa Hilado acquired 1,422 shares of the company’s stock in a transaction dated Friday, November 11th. The shares were purchased at an average price of $210.64 per share, with a total value of $299,530.08. Following the completion of the acquisition, the chief financial officer now owns 12,659 shares in the company, valued at $2,666,491.76. The disclosure for this purchase can be found here. 0.27% of the stock is owned by company insiders.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.